Stockreport

NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study

ABLIVA AB  (NEVPF) 
NASDAQ:AMEX Investor Relations: neurovive.com/investor
PDF LUND, Sweden, 4 July 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that the company has initiated the second pa [Read more]